Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 02

64P - Clinical profile and treatment outcome of patients with non-metastatic colon cancer: A single institutional study from India

Date

03 Dec 2022

Session

Poster viewing 02

Presenters

Sandip Ganguly

Citation

Annals of Oncology (2022) 33 (suppl_9): S1445-S1453. 10.1016/annonc/annonc1122

Authors

S. Ganguly1, N. Mukherjee1, K. Ray1, S. Mandal1, A. Dasgupta1, M. Mallath2, T. Chawla3, M. Ray4, A. Pipara4, B. Biswas5, S. Roy1, J. Ghosh5

Author affiliations

  • 1 Medical Oncology, TMC - Tata Medical Center, 700160 - Kolkata/IN
  • 2 Digestive Disease, TMC - Tata Medical Center, 700160 - Kolkata/IN
  • 3 Clinical Pharmacology, TMC - Tata Medical Center, 700160 - Kolkata/IN
  • 4 Surgical Oncology, TMC - Tata Medical Center, 700160 - Kolkata/IN
  • 5 Medical Oncology, Tata Medical Center, 700160 - Kolkata/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 64P

Background

Colo rectal cancer is the third most common cancer in the world. Clinical data on localized colon cancer and treatment outcome is scarce in the literature. This is a real-world study of the clinical profile and treatment patterns and outcomes of patients with nonmetastatic colon cancer from India. Here we report our experience in this patient population.

Methods

This is a retrospective chart review of patients with nonmetastatic colon cancer registered in our hospital from May 2011 to December 2021. Patients who presented with recurrent metastatic disease were included in this review if the treatment details for the localized disease were available. The baseline demographic features and treatment details and toxicity were recorded.

Results

Total of 1084 patients were registered during this time period. The median age of the population was 60 (9-91 )years. Males constituted 648 (60%) of cases. The most common site of the primary was descending and sigmoid colon (41%). Majority of the patients had stage III disease (46.5%). Most of our patients received capecitabine and oxaliplatin-based combination therapy. The median disease-free survival is 30.7 months.

Conclusions

Most common site of colon cancer is the left side and stage III is the most common stage of presentation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.